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1 Tel.: +966 38911828x414/124 (work), mobile: +966 542406808.Ashbala Khattak a,⇑; Fouad R. Nakhli b,1; Haider R. Cheema cAbstractAims: To determine the short-term efficacy of corneal collagen crosslinking (CXL) treatment in patients with progressive
Keratoconus (KCN) in comparison with no treatment.
Settings and design: This controlled clinical trial study was carried out at a tertiary eye hospital, Eastern Province, Saudi Arabia.
Methods and material: A prospective controlled clinical study of patients being treated for Keratoconus at a tertiary eye care
hospital in the Eastern province of Saudi Arabia. 51 eyes of 43 patients with progressive KCN who received corneal collagen
crosslinking (treatment group) and 50 eyes of 34 patients with KCN and no treatment (control group) were included in our study.
A one year clinical data were collected preoperatively as well as at 1, 3, 6 and 12 months postoperatively for the treatment group
patients. A baseline and 1 year clinical data were collected for the control group patients. The short-term efficacy of the treatment
in preventing progression of KCN in comparison with no treatment was analysed at one year.
Results: At one year after crosslinking, there was significant flattening of the average keratometry by 0.61 D (p = 0.001) [95% CI:
0.25, 0.97] compared to 0.40 D (p = 0.210) steepening in the control group; difference between treatment and control was 1.01 D
(p = 0.006) [95%CI: 0.29, 1.72]. Pachymetry in treatment group thinned by 20.21 lm (p < 0.0001) [95% CI: 12.77, 27.66] compared
to 0.32 lm (p = 0.912) in the control group. Visual acuity remained stable at the preoperative level of 20/30 (p = 0.397) in the
treatment group and 20/40 (p = 0.553) in the control group at one year.
Conclusions: Corneal CXL is an effective treatment for halting the progression of KCN as shown by reduced keratometry and
stability of vision.
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Keratoconus (KCN) is a progressive degenerative disease
of the cornea, usually bilateral, however asymmetric.1 It
affects mostly young patients, and an early age of onset is
a negative prognostic factor for corneal transplantation.2There are several treatment options available, depending
on the stage of KCN. However, none of these options restore
vision to a near normal vision. Recently, there has been a
major breakthrough in blocking the progression of the
disease in the form of corneal collagen crosslinking with
Riboflavin and Ultraviolet A (UVA) light.3,4 This treatment
when offered to patients with progressive KCN and, treatede:
al.com
abia
250 A. Khattak et al.early, can dramatically improve the outcome of KCN, espe-
cially in younger patients.
KCN is a very common corneal ectasia in Saudi Arabia and
accounts for high percentage of corneal transplants in Saudi
Arabia.5 No controlled studies have been conducted report-
ing results of corneal collagen crosslinking with Riboflavin
and UVA in patients with KCN in Saudi Arabia. The aim of this
prospective controlled study was to report our results of
collagen crosslinking treatment in comparison with no treat-
ment over a period of one year in Saudi population with KCN.Subjects and methods
The study was conducted at a tertiary care ophthalmic
hospital in Eastern Province of Saudi Arabia. It was approved
by institutional review board of the hospital. The inclusion cri-
teria for the treatment group was diagnosis of KCN, with
either subjective worsening of vision or at least one diopter
steepening of the cornea on keratometry over a period of
one year and, the thinnest corneal pachymetry of more than
400 lm. The exclusion criteria were patients with previous
intracorneal segments placement, severe dry-eye, and cor-
neal pachymetry less than 400 lm, central corneal scar or
no subjective or objective progression of KCN. The matched
control group patients were randomly selected from our
medical records, patients who had been diagnosed with
KCN but did not undergo any intervention for treatment of
KCN during their follow-up in the clinic. These patients were
historic controls and did not undergo any treatment as CXL
was not readily available as treatment modality in the past.
A full ocular assessment, including the measurement of
pre-operative Visual acuity, Refraction and, Specular
Microscopy (Konan Medical, Inc., Hyogo, Japan), was carried
out for all patients undergoing corneal collagen crosslinking.
Best Corrected Visual Acuity (BCVA), refraction and
Pentacam measurements were repeated at every subsequent
visit.Table 1. Topographic and refractive changes over 1, 3, 6, and 12 months from
Parameter Pre-treatment
Mean ± SD
Post-treatm
Post treatm
Average keratometry Kav 47.35 ± 3.81 1 month
3 months 0.53
6 months 0.73
12 months 0.61
Maximum keratometry Kmax 55.03 ± 7.39 1 month
3 months 0.61
6 months 1.39
12 months 0.54
Asphericity Q value 0.82 ± 0.53 1 month
3 months 0.018
6 months 0.07
12 months 0.093
Pachymetry thinnest (lm) 460.53 ± 27.80 1 month
3 months 32.03
6 months 21.12
12 months 20.21
Spherical equivalent (D) 3.37 ± 3.32 1 month
3 months 0.30
6 months 0.14
12 months 0.02
Best Corrected Visual Acuity (Decimal) 0.63 ± 0.26 1 month
3 months 0.142
6 months 0.010
12 months 0.029Collagen crosslinking technique
An informed consent was obtained from all patients
undergoing the procedure. The eye to be treated was
prepped with Iodine and topical anesthesia. A lid speculum
was used. An 8 mm zone was treated with an 8 mm sponge
soaked in 20% alcohol for 20 s followed by rigorous irrigation
to wash out any residual alcohol. The epithelium was
removed with cellulose sponges. Pachymetry was performed
after epithelium removal to ascertain that it was more than
400 lm. A 3.0 ml single use isotonic solution of Riboflavin
(>0.1%) with Dextran500 (20%) (LightMed Corporation, New
Taipei City, Taiwan), was instilled in the eye every 4 min
and Balanced Salt Solution (BSS) every two minutes for a total
of 30 min. Pachymetry was obtained at the end of 30 min to
make sure the corneal thickness was still more than 400
microns before the UVA light application. UVA light from
VEGA CBM-X-Linker (Costruzione Strumenti Oftalmici, or
CSO, Italy) with cropped light beam of 9 mm diameter was
applied for 30 min with 3 mW/cm2 energy. Riboflavin drops
and BSS were continued in the same manner during UVA
irradiation. At the end of procedure, a bandage contact lens
was applied. The patient was instructed to use antibiotic
Vigamox (Alcon, Dallas Fort Worth, USA) and steroid eye
drops, Vexol (Allergan, Irvine California, USA) four times a
day for a week following the procedure. The steroid drops
were gradually tapered over 1 month and antibiotics were
discontinued after one week. Patients were followed in clinic
at post-op day one, 1 week, 1 month, 3 months, 6 months
and then one year after the procedure.Statistical analysis
Independent t-test for parametric data, and one way
repeated-measure ANOVA were performed with SPSS sta-
tistical software (version 17.0.1, IBM Corp., Somers, NY,
USA) to compare groups and trends. p < 0.05 wasbaseline in treatment group.
ent
ent interval Difference value from
baseline
95% confidence
interval
p-value
0.74 0.23,1.26 0.006
1.06,0.01 0.054
1.17,0.29 0.002
0.97,0.25 0.001
1.11 0.18,2.40 0.091
1.94,0.72 0.362
2.29,0.49 0.003
1.73,0.66 0.371
0.157 0.25,0.06 0.001
0.10,0.06 0.654
0.01,0.15 0.080
0.004,0.18 0.042
38.69 49.25,28.13 <0.001
39.32,24.74 <0.001
28.68,13.55 <0.001
27.66,12.77 <0.001
0.49 3.26,4.24 0.794
0.63,1.23 0.516
1.11,0.83 0.769
0.55,0.60 0.935
0.08 0.27,0.42 0.663
0.02,0.27 0.028
0.07,0.09 0.790
0.04,0.10 0.397
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regression models were used to investigate influencing
factors such as age and gender.Results
Fifty eyes of 43 (34 males and 9 females) patients with a
mean age of 24.81 ± 6.71 years and age range 12–42 years
with Keratoconus were included in the treatment group.
Fifty eyes of 33 patients (20 males and 13 females) with mean
age 28.18 ± 6.00 years and age range 16–41 years with
Keratoconus were included in the control group.
In repeated measurement/paired/matched (pre-post)
design, the same eye acted as control (preoperative/un-
treated) case and treatment (postoperative/treated) case. It
constituted the perfect match in every aspect. Noting this,
our study compared changes and not the baseline measure-
ments or the end measurements.Keratometry
The average Keratometry of treatment group steepened
by 0.74 D in immediate postoperative at 1 month (Table 1,
Fig. 1A). However, at 12 months, flattening by 0.61 D was
noted (p-value 0.001) (Table 1); the control group, on the
other hand, steepened by 0.40 D (p-value 0.21) over one year
(Table 2). At one year, treatment group compared to control
group, flattened by 1.00 D (p-value 0.006) (Fig. 1B).
Incidentally, a difference between responses of males and
females to treatment was also noted (Fig. 1C): malesFigure 1. (A) Keratometry trends over one year in the treatment group. (B) Com
at one year. (C) Maximum keratometry difference between control and treatm
Table 2. Topographic changes at 12 months from baseline in treatment and co
Parameter Control group
Baseline
mean ± SD
Change at
1 year
Confidence
interval
Average keratometry Kav (D) 50.77 ± 7.77 0.40 0.23,1.03
Maximum keratometry (D) 61.02 ± 13.99 1.14 0.86,3.13
Asphericity 0.98 ± 0.77 0.09 0.24,0.06
Pachymetry thinnest (lm) 441.90 ± 65.64 0.32 6.14,5.50
Spherical equivalent (D) 4.53 ± 4.98 0.29 0.97,0.39
Best Corrected Visual
Acuity (Decimal)
0.58 ± 0.33 0.02 0.04,0.08(malesnt malest) flattened more by 0.81 D (p-value 0.005)
compared to females (femalesnt  femalest).
The maximum Keratometry of treatment group steepened
by 1.11 D (p-value 0.091) in the immediate postoperative
period at 1 month, and by 12 months flattening was noted
with an average of 0.54 D (p-value 0.371) (Table 1) whereas
those of control group steepened by 1.14 D (p-value 0.259)
over one year (Table 2). Compared to control group, treat-
ment group flattened by 1.67 D (p-value 0.152) (Fig. 1B);
males (malesnt malest) flattened by 3.12 D (p-value 0.029)
compared to females (femalesnt  femalest) (Fig. 1C).Pachymetry
At one month postoperatively, pachymetry at the thinnest
location showed thinning by 38.69 lm (p-value < 0.000). At
12 months, thinning became less at 20.21 lm (p-
value < 0.0001) (Table 1 and Fig. 2A). On the contrary,
control corneas thinned by 0.32 with a p-value of 0.912 by
12 months (Table 2); treatment corneas thinned by
19.89 lm (p-value < 0.0001) compared to control corneas
(Fig. 2B); males (malesnt malest) thinned more than females
(femalesnt  femalest) by 22.90 lm (p-value < 0.0001)
(Fig. 2C).Corneal shape
Corneas took a more prolate shape in the treatment
group, as asphericity increased by 0.152 (p-value 0.001)
one month postoperatively. This decreased by 0.093 (less
prolate) (p-value 0.042) at 12 months (Table 1 and Fig. 3A).parison of maximum keratometry between treatment and control groups
ent groups based on gender.
ntrol groups.
Treatment group
p-value Baseline
mean ± SD
Change at
1 year
Confidence
interval
p-value
0.210 47.35 ± 3.81 0.61 0.97,0.25 0.001
0.259 55.03 ± 7.39 0.54 1.73,0.66 0.371
0.231 0.82 ± 0.5 0.093 0.004,0.18 0.042
0.912 460.53 ± 27.80 20.21 27.66,12.77 <0.001
0.398 3.37 ± 3.32 0.02 0.55,0.60 0.935
0.553 0.63 ± 0.26 0.029 0.04,0.1 0.397
Figure 2. Pachymetry changes over one year in treatment and control groups. (A) Treatment group pachymetry trend over one year. (B) Change in the
thinnest pachymetry over one year in the treatment and control groups. (C) Change in the pachymetry over one year per gender per group.
Figure 3. (A) Trend in the asphericity over one year in the treatment group. (B) Asphericity difference between control and treatment groups at one year.
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0.090 (p-value 0.231) at 12 months (Table 2). The treatment
corneas differed by 0.182 (p-value 0.037) (less prolate) from
control corneas (Fig. 3B); also males (malesnt malest) dif-
fered by 0.291(less prolate) (p-value 0.006) from females
(femalesnt  femalest).
Refraction
Spherical equivalent of treatment group had a hyperopic
shift by 0.49 D (p-value 0.794) in immediate postoperative
period at 1 month; by 12 months, hyperopic shift was
0.024 D (p-value 0.935) (Table 1) whereas those of control
group had myopic shift by 0.29 D (p-value 0.398) over one
year (Table 2); compared to control group, treatment group
had a hyperopic shift by 0.31 D (p-value 0.483).
Visual acuity
The mean baseline Best Corrected Visual Acuity of treat-
ment group was 20/30 preoperatively; after treatment, it
quickly lost one line (0.142) to 20/40 (p-value 0.028).
However, it regained the loss and improved to pre-opbaseline level at 20/30 (p-value 0.397) at the end of the year
(Table 1). The control group, on the other hand, maintained
visual acuity at 20/40 (p-value 0.553) (Table 2). The difference
between control and treatment groups was 0.011 (p-value
0.799).Discussion
There is high prevalence of KCN in Saudi Arabia.6 The
onset of disease is usually very early with rapid deterioration
of vision which often times requires a corneal transplant.5–7
The available treatment in the form corneal collagen
crosslinking is projected to dramatically change the visual
prognosis in the long run.
Collagen crosslinking as a treatment option is commonly
offered to progressive KCN patients in all tertiary level oph-
thalmic care hospitals in Saudi Arabia. However, very little
has been published about the results of this procedure in this
part of the world, where a very early onset and severe pre-
sentation of the disease is not uncommon.5 We studied our
KCN patient population that was treated with collagen
crosslinking treatment. We also randomly selected clinical
Corneal collagen crosslinking for progressive keratoconus 253controls with the comparable demographics to investigate
their progression and justify crosslinking for all KCN patients.
Our findings in the study are not vastly different from the
published data on crosslinking throughout the world.8–12,14
Although, there was deterioration of BCVA at 1 and
3 months, all our patients in the intervention group were able
to either maintain or improve their Best Corrected Visual
Acuity at the end of 12 month period. In this respect, our
study shows results comparable to published results showing
stability,8,13 or improved visual outcome after crosslink-
ing.10,11,14–16 The keratometry K1, K2, Kmax, Kav of the inter-
vention group showed a marked steepening in the 1 and
3 months post op period. However, it returned back to base-
line at 1-year (Fig. 1A). On an average, there was a 1-diopter
flattening at 1-year in the treatment group which is similar to
the data in literature.12,17,18 On the other hand, the control
group had a trend towards steeping keratometry at one year.
Keratoconus is a slowly progressive disease and one year may
not be enough time to show clinically significant progression
in the control group.19,20
The corneal pachymetry in treatment group decreased
dramatically in the initial 3 months post treatment, which
slowly crept towards the baseline, however, not to the
preoperative level in any case (Fig. 2A). In our study-pop-
ulation this detriment of corneal thickness post crosslinking
is relatively more than other study populations.21–24 The rea-
son of thinner pachymetry post crosslinking is not fully under-
stood but may be explained by more compact structure due
to increased interfibrillar and intrafibrillar chemical bonds,25–27
keratocyte apoptosis,20,28,29 epithelial remodelling, and
changes in glycosaminoglycans.27,30 Many studies have
shown that these bonds in the corneal stroma after crosslink-
ing increase the tensile strength of the cornea despite the
fact the cornea is thinner postprocedure.31–34 Our control
group also had mild progressive thinning of the cornea over
a period of time, which is explained by the natural progres-
sion of the disease rather than any structural modification.
Again one year may not be enough to show marked thinning
in the control group.
The asphericity of the cornea decreased over time, which
is consistent with the flattening of the cornea. A study by
Hersh et al. had showed significant decrease in higher order
aberrations after crosslinking.35 The refractive error (spherical
equivalent) went through the same change of worsening ini-
tially and then returning back to baseline. The control group
remained to have stable refractive error over one-year.
Vinciguerra et al. concluded that refractive outcomes were
achieved by both flattening of the cone apex and a steepen-
ing of the part of the cornea symmetrically opposite to the
cone.14 In conclusion, in our population, after crosslinking
there is rapid deterioration of BCVA, average keratometry,
pachymetry and, astigmatism mostly at one month which
gradually returns back to baseline at one year with the excep-
tion of pachymetry.
Interestingly we found a difference in corneal response to
crosslinking between males and females. Our male patients
responded more effectively to the treatment as compared
to the female patients as to average and maximum ker-
atometry, pachymetry, and asphericity. This difference has
not been noted yet in the published data according to our
knowledge. It needs to be explored more with further
studies.No patients who underwent corneal collagen crosslinking
had any sight threatening complications. The epithelial
defect created iatrogenically at time of surgery healed within
a week time for all patients. There was a mild corneal haze
after crosslinking in some patients; however, it was visually
insignificant.
In summary, we conclude from our study that crosslinking
is an effective treatment in eyes with progressive
Keratoconus by significantly reducing average mean K read-
ings and decreasing asphericity, after one year follow-up.
Further clinical studies with longer follow-up are needed to
determine the efficacy of the CXL in time, despite the fact
that the results of this study are promising for a long-term
efficacy.
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